石药(01093.HK)向Radiance Biopharma授出SYS 6005独家开发权

阿斯达克财经
Feb 19, 2025

石药集团(01093.HK) 公布,其附属石药巨石已与Radiance Biopharma就集团的重组抗人类受体酪氨酸激酶样孤儿受体1 (ROR1)抗体偶联药物SYS 6005,在美国、欧盟、英国、瑞士、挪威、冰岛、列支敦士登、阿尔巴尼亚、黑山、北马其顿、塞尔维亚、澳洲和加拿大的开发及商业化订立独家授权协议。据此,石药巨石同意授予Radiance Biopharma在该地区开发及商业化该产品的独家...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10